Susanna Vogel

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

Multiple factors could get in the way of confirming a new commissioner until after the midterm elections, experts said, leaving the agency's long-term initiatives in limbo.

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.

Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.